Use of Intravenous Immunoglobulin and Rituximab for the prevention and treatment of antibody-mediated rejection

被引：0
|
作者：
Jordan, S. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Dept Med, Comprehens Transplant Ctr, Los Angeles, CA 90048 USA
来源：
XENOTRANSPLANTATION | 2009年 / 16卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：330 / 331
页数：2
相关论文
共 50 条
  • [21] Outcomes of Combination Therapy of Rituximab and High-Dose Intravenous Immunoglobulin for Chronic Antibody-Mediated Rejection in Renal Transplantation
    Kim, Y. J.
    Kim, M. -G.
    Ro, H.
    Yun, I. J.
    Ahn, C.
    Yang, J.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 290 - 290
  • [22] Clinical Outcome of Rituximab and Intravenous Immunoglobulin Combination Therapy in Kidney Transplant Recipients with Chronic Active Antibody-Mediated Rejection
    Ban, Tae Hyun
    Yu, Ji Hyun
    Chung, Byung Ha
    Choi, Bum Soon
    Park, Cheol Whee
    Kim, Yong-Soo
    Yang, Chul Woo
    [J]. ANNALS OF TRANSPLANTATION, 2017, 22 : 468 - 474
  • [23] Effectiveness of Rituximab and Intravenous Immunoglobulin for the Treatment of Chronic Antibody Mediated Rejection in Kidney Transplant Recipients.
    An, G.
    Chung, B.
    Park, C.
    Choi, B.
    Kim, Y.
    Yang, C.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 328 - 328
  • [24] Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients
    Bujnowska, A.
    Michon, M.
    Konopelski, P.
    Hryniewiecka, E.
    Jalbrzykowska, A.
    Perkowska-Ptasinska, A.
    Cieciura, T.
    Zagozdzon, R.
    Paczek, L.
    Ciszek, M.
    [J]. TRANSPLANTATION PROCEEDINGS, 2018, 50 (06) : 1720 - 1725
  • [25] Plasma Exchange and Intravenous Immunoglobulin in Treatment of Antibody-Mediated Rejection after Kidney Transplantation: Slovenian Experience
    Gubensek, J.
    Ponikvar, Buturovic J.
    Kandus, A.
    Arnol, M.
    Kovac, J.
    Marn-Pernat, A.
    Lindic, J.
    Kovac, D.
    Ponikvar, R.
    [J]. TRANSPLANTATION, 2012, 94 (10) : 1026 - 1026
  • [26] Rituximab for Antibody-Mediated Rejection, Less May Be More
    Mulley, William R.
    Kanellis, John
    [J]. TRANSPLANTATION, 2009, 88 (01) : 142 - 143
  • [27] INTRAVENOUS IMMUNOGLOBULIN ADMINISTRATION FOR DESENSITIZATION BEFORE RENAL TRANSPLANTATION AND MANAGING ANTIBODY-MEDIATED REJECTION
    Sushkov, A. I.
    Moysyuk, Y. G.
    [J]. VESTNIK TRANSPLANTOLOGII I ISKUSSTVENNYH ORGANOV, 2011, 13 (02): : 110 - 121
  • [28] COMPARISON OF THE TREATMENT EFFICACY OF RITUXIMAB AND PLASMAPHERESIS/INTRAVENOUS IMMUNOGLOBULIN COMBINATION WITH HISTORICAL CONTROL IN CHRONIC ANTIBODY MEDIATED REJECTION
    Ruhi, Caglar
    TugCu, Murat
    KasapogLu, Umut
    Gokce, Ali Murat
    Ata, PiNar
    Titiz, IZzet Mesut
    [J]. TRANSPLANT INTERNATIONAL, 2017, 30 : 300 - 301
  • [29] Antibody-mediated rejection after cardiac transplant: Treatment with immunoadsorption, intravenous immunoglobulin, and anti-thymocyte globulin
    Sipahi, Nihat Firat
    Saeed, Diyar
    Makimoto, Hisaki
    Mehdiani, Arash
    Akhyari, Payam
    Dalyanoglu, Hannan
    Reinecke, Petra
    Lichtenberg, Artur
    Boeken, Udo
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2019, 42 (07): : 370 - 373
  • [30] Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection
    Waiser, Johannes
    Budde, Klemens
    Schuetz, Manuela
    Liefeldt, Lutz
    Rudolph, Birgit
    Schoenemann, Constanze
    Neumayer, Hans-H
    Lachmann, Nils
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (03) : 1246 - 1251
12345